Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: Clinical study of 26 cases

The clinical findings in 26 patients in whom hepatocellular carcinoma (HCC) was detected after the start of interferon (IFN) therapy for chronic hepatitis C were analysed. Histological study before IFN therapy showed that 34.6% of patients were categorized as stage 3 (septal fibrosis with architectural distortion; the 0–4 scale) and 80.8% demonstrated at least some evidence of septal fibrosis or more advanced features. The AFP levels examined before IFN therapy were more than 20 ng/mL in 13 patients (84.6% of those studied). One of 26 patients had a complete response to IFN therapy, while six of 26 patients had only a partial response. HCC was detected within 1 year after the start of IFN therapy in 76.9% of patients. Thus, the possibility of the early occurrence of HCC or its existence at the time of therapy should be seriously considered when IFN therapy is contemplated. Patients with stage 3 or 3–4 histology may already have a small undetectable HCC before IFN therapy. Thus, for this reason, every patient treated with IFN should be examined at short regular intervals for the development of HCC during and after IFN therapy.     

Asymptomatic autoimmune chronic active hepatitis in a male adolescent

We report a 12-year-old boy presenting with smooth muscle antibody-positive auto-immune chronic active hepatitis. Suspicion of the diagnosis arose after a routine blood test which revealed abnormal liver function tests. In spite of the presence of cirrhosis and patchy necrosis on liver biopsy, our patient never showed any clinical feature of impaired liver function. This observation demonstrates that auto-immune hepatitis may exist for a long time before clinical symptoms appear and probably explains why some cases of auto-immune hepatitis finally present as fulminant liver failure.     

HCV HVR1准种在不同基因型丙型肝炎患者中的分布

目的:通过研究丙型肝炎病毒高变区1(HCV HVR1)准种复杂性与基因型之间的关系,探讨不同基因型HCV致病性差异的机制.方法:采用C区型特异性引物PCR法进行HCV基因分型,采用单链构象多态性聚合酶链反应法(SSCP法)检测HCV HVR1准种.结果:68例丙型肝炎患者中,Ⅱ型49例(72%),Ⅲ型13例(19%),Ⅱ、Ⅲ混合型6例(9%).Ⅱ型和Ⅱ、Ⅲ混合型HCV感染患者的HCV HVR1准种复杂性(SSCP条带数)明显高于Ⅲ型感染的患者,且与疾病严重程度关系密切.结论:HCV HVR1准种复杂性的差异可能是导致不同基因型HCV致病性差异的因素之一.     

血浆置换床边治疗重型肝炎临床观察

目的探讨血浆置换(简称PE)床边治疗重型肝炎的临床疗效。方法60例病例采用常规内科治疗加PE治疗,比较PE治疗前后临床症状缓解时间及血生化变化。结果临床症状缓解迅速,黄疸减退,白蛋白、胆碱脂酶升高,PT恢复,补体上升,不影响肾功及电解质。结论PE为重型肝炎一种行之有效的治疗方法。     

抗戊型肝炎病毒重组蛋白单克隆抗体的制备和初步应用

目的:制备抗-戊型肝炎病毒的单克隆抗体,并将其用于分析戊型肝炎病毒不同毒株结构蛋白的抗原表位。方法:采用来自墨西哥株(Mexicanstrain)的戊型肝炎病毒重组蛋白(p166Mex)免疫Balb/c小鼠,取其脾细胞与SP2/0骨髓瘤细胞进行融合,经酶联免疫吸附试验(ELISA)法筛选阳性克隆,并将获得的单克隆抗体与戊型肝炎病毒缅甸株(Burmastrain)和美国株(USAstrain)的重组蛋白(p166Bur、p166US)进行交叉反应测定。结果:最终获得4株能稳定分泌抗-p166Mex的杂交瘤细胞株,即D8G10、E5E12、D4A3、B7E6。其中D8G10,E5E12和B7E6细胞株的培养上清液,还能分别与p166Bur和p166US重组蛋白发生阳性反应。结论:利用已获得的抗-p166Mex单克隆抗体,初步确定3种不同的戊型肝炎病毒重组蛋白(p166Bur、p166US、p166Mex)含有一种共同的抗原表位。     

湖南省乙肝病毒基因型分布及临床意义

目的 :研究湖南省乙肝病毒 (HBV)基因型分布及临床意义。方法 :选择湖南省HBVDNA阳性慢性乙肝病人共 185例 ,其中病毒携带者 (ASC) 4 2例 ,慢性轻、中度肝炎 (CH) 38例 ,重型肝炎 (FHF) 80例 (伴有肝硬化者 4 9例 ) ,肝细胞癌 (HCC) 2 5例 ,采用聚合酶链反应 限制性片段长度多态性 (PCR RFLP)方法检测HBV基因型。结果 :基因型B136例 (73.5 % ) ,基因型C 4 9例 (2 6 .5 % )。基因型B在FHF中占绝对优势 (83.7% ) ,其次为HCC(76 % ) ,与ASC(5 7.1% )比较 ,差异有显著性 (P <0 .0 1)。与基因型B相比 ,基因型C在垂直传播感染者中多见 (38.8%与 13.2 % ,P <0 .0 0 1) ;HBeAg阳性率明显增高 (5 7.1%与 30 .9% ,P <0 .0 0 1) ;抗HBe阳性率明显下降 (36 .9%与 6 6 .2 % ,P <0 .0 0 1)。与基因型C相比 ,基因型B感染者ALT水平明显增高 (2 6 4 .5± 2 5 6 .5与 10 0± 12 0 .6 ,P <0 .0 0 1)。结论 :湖南省存在乙肝病毒基因型B和基因型C ;基因型B为优势基因型并与肝脏疾病活动性相关 ,基因型C与母婴垂直传播感染有关     

巨细胞病毒肝炎患儿血清细胞因子水平测定及其临床意义

目的　研究巨细胞病毒 (CMV)肝炎患儿血清干扰素 α(IFN α)、白细胞介素 8(IL 8)和肿瘤坏死因子 α(TNF α)水平的变化及其临床意义。方法　应用ELISA法检测 35例CMV肝炎患儿血清中上述三种细胞因子的含量 ,并对其两两之间进行了相关性分析。结果　CMV肝炎组患儿IFN α、IL 8、TNF α的含量分别为 (770 .3± 2 0 5 .4 )ng/L、(41.9± 2 2 .5 )ng/L和 (10 33.2± 388.5 )ng/L ,非常显著高于正常对照组 (P <0 .0 1)。相关性研究发现IFN α与TNF α呈显著正相关 (r =0 .35 6 ,P <0 .0 5 )。结论　血清细胞因子明显增高与CMV肝炎的病理变化和病损程度有着密切的联系     

Immunogenicity study of low-dose administration of hepatitis B virus vaccine in newborn infants: A cost reduction trial

Different doses of hepatitis B virus vaccine—prepared by Korea Green Cross Corporation, were given to healthy infants born to HBsAg-negative mothers at birth, 1 and 6 months of age. A dose of 2 μg was administered intradermally in Group A and, in the three other groups, the vaccine was given intramuscularly (i.m.). An adequate follow-up observation was possible for 9 months after birth in 22, 25, 23 and 21 infants in Groups A, B, C and D, respecvely.
Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age.
While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization.     

对拉米夫定耐药的慢性乙型肝炎病人治疗研究现状

核苷类似物拉米夫定于1998年在我国上市，为乙型肝炎的抗病毒治疗带来了新的希望。然而持续的拉米夫定治疗会使病人产生耐药从而导致严重后果。本文对这部分病人的抗病毒治疗进展进行综述。     

急性重症肝炎患者发生肝性脑病危险因素多元Logistic回归研究

目的探索急性重症肝炎患者发生肝性脑病的危险因素，以便进行早期干预。方法收集血浆凝血酶原时间（PT）延长，活动度〈40％的急性重症肝炎患者69例，对69例患者的年龄、性别和基础疾病等临床背景资料和总胆红素、直接胆红素、谷草转氨酶（AST）、谷丙转氨酶（ALT）、血浆白蛋白、胆碱脂酶、血浆凝血酶原时间（PT）、白细胞计数（WBC）、血小板计数（Plt）等实验室检查数据进行单因素分析和多元Logistic回归分析。结果单因素分析和多元Logistic回归分析均提示年龄、血胆红素水平和血浆凝血酶原时间在肝性脑病组和非肝性脑病组之间有统计学差异。结论约30％的急性重症肝炎患者发展成为肝性脑病。高龄、血浆凝血酶原时间延长、活动度下降、高血浆总胆红素等是急性重症肝炎患者发展成为肝性脑病的潜在危险因素。